Search - tctmd.com

Displaying 121 - 140 of 250

Sort: Relevancy | Date

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Shelley Wood

March 10, 2020

News Daily News

Meat Consumption Linked to Small Rises in CVD, All-Cause Mortality Risks

Michael O'Riordan

February 05, 2020

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Daily News

Decline in US Deaths From CVD and Diabetes Is Leveling Off

Todd Neale

August 27, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Genes Bolster Case for Link Between Insomnia and CV Risk

Alison Palkhivala

August 19, 2019

News Daily News

Bariatric Surgery Linked to Survival Advantage After MI and CVA

Michael O'Riordan

May 13, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Daily News

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Michael O'Riordan

April 10, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

Advertisement

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Meat Consumption Linked to Small Rises in CVD, All-Cause Mortality Risks

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Decline in US Deaths From CVD and Diabetes Is Leveling Off

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Genes Bolster Case for Link Between Insomnia and CV Risk

Bariatric Surgery Linked to Survival Advantage After MI and CVA

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content